Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Hetero-Biopharma"

5 News Found

Hetero gets CDSCO approval to manufacture and sell Sputnik Light in India
News | March 21, 2022

Hetero gets CDSCO approval to manufacture and sell Sputnik Light in India

Sputnik Light is the first component of Sputnik V

India grants Emergency Use Authorisation to Sputnik Light
News | February 07, 2022

India grants Emergency Use Authorisation to Sputnik Light

This is the ninth Covid-19 vaccine approved in India

RDIF offers vaccine for adolescents aged 12-17 in India
News | December 07, 2021

RDIF offers vaccine for adolescents aged 12-17 in India

Sputnik M is a new member of the Sputnik vaccines family

DGCI approves Hetero’s Tocilizumab
Drug Approval | September 06, 2021

DGCI approves Hetero’s Tocilizumab

Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month

RDIF and Morepen announce production of test batch of Sputnik V
News | July 08, 2021

RDIF and Morepen announce production of test batch of Sputnik V

The first batch will be shipped to the Gamaleya Center for the quality control

Latest Stories

Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr

Sigachi Industries signs MoU with Respilon Group

USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging